UBS Group AG Has $14.61 Million Position in Heartflow, Inc. $HTFL

UBS Group AG increased its holdings in shares of Heartflow, Inc. (NASDAQ:HTFL) by 228.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 501,165 shares of the company’s stock after acquiring an additional 348,753 shares during the period. UBS Group AG owned about 0.59% of Heartflow worth $14,609,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in HTFL. Legal & General Group Plc acquired a new stake in shares of Heartflow during the 3rd quarter valued at about $59,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Heartflow during the 3rd quarter valued at about $234,000. Legato Capital Management LLC acquired a new stake in shares of Heartflow during the 3rd quarter valued at about $243,000. Sandia Investment Management LP acquired a new stake in shares of Heartflow during the 3rd quarter valued at about $252,000. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Heartflow during the 3rd quarter valued at about $288,000.

Insider Buying and Selling at Heartflow

In related news, Director Julie A. Cullivan sold 9,122 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $25.00, for a total transaction of $228,050.00. Following the completion of the sale, the director directly owned 27,291 shares of the company’s stock, valued at $682,275. The trade was a 25.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $29.23, for a total transaction of $27,732,167.11. Following the completion of the sale, the insider directly owned 8,448,158 shares of the company’s stock, valued at $246,939,658.34. The trade was a 10.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 2,205,874 shares of company stock valued at $64,166,729. 7.70% of the stock is currently owned by corporate insiders.

Heartflow Price Performance

HTFL opened at $31.20 on Thursday. The company has a market cap of $2.69 billion and a price-to-earnings ratio of -15.68. The firm has a 50 day simple moving average of $27.02 and a 200 day simple moving average of $28.91. Heartflow, Inc. has a fifty-two week low of $20.13 and a fifty-two week high of $41.22.

Analyst Ratings Changes

A number of equities analysts have commented on HTFL shares. William Blair started coverage on shares of Heartflow in a research report on Monday, May 4th. They issued an “outperform” rating on the stock. Wells Fargo & Company reduced their price target on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Canaccord Genuity Group boosted their price target on shares of Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, March 19th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday, March 19th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.67.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.